OTC Obesity - Austria

Date: April 22, 2010
Pages: 31
Price:
US$ 990.00
Publisher: Euromonitor International Ltd
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O1A8D31B2E3EN
Leaflet:

Download PDF Leaflet

GlaxoSmithKline’s Alli was introduced in April 2009, as in all other European countries. The sales for 2009 were estimated at EUR100,000. This corresponds to a minimum of 520 consumers, assuming an average price of EUR0.80 per Alli pill once a day, used for eight months in 2009. While slimming products were not taken seriously in 2009, this product is likely to be considered as effective support for weight loss.

Euromonitor International's OTC Obesity Products in Austria report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.

Product coverage:

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
  • Get a detailed picture of the Consumer Health industry;
  • Pinpoint growth sectors and identify factors driving change;
  • Understand the competitive environment, the market’s major players and leading brands;
  • Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town and Santiago and a network of over 600 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
Executive Summary
Vat on Non-prescription Medicines Reduced From 20% To 10%
Health Increasingly Associated With Lifestyle
Bayer the Clear Leader in Consumer Health
Parapharmacies/drugstores Stronger
Future Impact of Tax Reduction Overestimated
Key Trends and Developments
Special Kind of Polarisation
Best Agers Driving Growth Sectors
Lifestyle Changes Impact Demand for OTC Products
Emotional Problems Affect Calming and Digestion
Market Indicators
  Table 1 Consumer Expenditure on Health Goods and Medical Services 2004-2009
  Table 2 Life Expectancy at Birth 2004-2009
Market Data
  Table 3 Sales of Consumer Health by Sector: Value 2004-2009
  Table 4 Sales of Consumer Health by Sector: % Value Growth 2004-2009
  Table 5 Consumer Health Company Shares by Value 2005-2009
  Table 6 Consumer Health Brand Shares by Value 2006-2009
  Table 7 Penetration of Private Label by Sector 2004-2009
  Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2004-2009
  Table 9 Sales of Consumer Health by Sector and Distribution Format: % Analysis 2009
  Table 10 Forecast Sales of Consumer Health by Sector: Value 2009-2014
  Table 11 Forecast Sales of Consumer Health by Sector: % Value Growth 2009-2014
Appendix
OTC Registration and Classification
Vitamins and Dietary Supplements Registration and Classification
Self-medication/self-care and Preventative Medicine
Switches
  Summary 1 OTC Healthcare Switches 2007-2009
Definitions
Sector and Subsector Definitions
  Summary 2 Research Sources
Apomedica GmbH & Co Kg
Strategic Direction
Key Facts
  Summary 3 Apomedica GmbH & Co KG: Key Facts
  Summary 4 Apomedica GmbH & Co KG: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 5 Apomedica GmbH & Co KG: Competitive Position 2009
Genericon Pharma Gesmbh
Strategic Direction
Key Facts
  Summary 6 Genericon Pharma GesmbH: Key Facts
  Summary 7 Genericon Pharma GesmbH: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 8 Genericon Pharma GesmbH: Competitive Position 2009
Kwizda F Joh GmbH
Strategic Direction
Key Facts
  Summary 9 Kwizda F Joh GmbH: Key Facts
  Summary 10 Kwizda F Joh GmbH: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 11 Kwizda F Joh GmbH: Competitive Position 2009
Sanova Pharma Gesmbh
Strategic Direction
Key Facts
  Summary 12 Sanova Pharma Gesmbh: Key Facts
Company Background
Production
Competitive Positioning
  Summary 13 Sanova Pharma Gesmbh: Competitive Position 2009
Wellness Co Gesmbh, the
Strategic Direction
Key Facts
  Summary 14 Wellness Co GesmbH, The: Key Facts
Company Background
Production
Competitive Positioning
  Summary 15 Wellness Co GesmbH, The: Competitive Position 2009
Trends
Category Data
  Table 12 Sales of OTC Obesity: Value 2009
  Table 13 OTC Obesity Company Shares by Value 2005-2009
  Table 14 OTC Obesity Brand Shares by Value 2006-2009
  Table 15 Forecast Sales of OTC Obesity: Value 2009-2014
  Table 16 Forecast Sales of OTC Obesity: % Value Growth 2009-2014
Skip to top


OTC Obesity - Australia US$ 990.00 Jun, 2010 · 33 pages
OTC Obesity - Denmark US$ 990.00 Apr, 2010 · 29 pages
OTC Obesity - France US$ 990.00 Apr, 2010 · 49 pages
OTC Obesity - Greece US$ 990.00 Mar, 2010 · 33 pages
OTC Obesity - Netherlands US$ 990.00 Jun, 2010 · 32 pages

Ask Your Question

OTC Obesity - Austria
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: